Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Encompass Health Corporation and its officers or directors [1] Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, alleged that Encompass's for-profit hospitals perform below average on key safety measures, including high rates of potentially preventable readmissions [3] - The article highlighted that Encompass owns 34 facilities rated by Medicare as having statistically significantly worse rates of potentially preventable readmissions [3] - Following the publication of the article, Encompass's stock price dropped by $12.39 per share, or 10.35%, closing at $107.28 per share on the same day [4]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Encompass Health (EHC) due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - Encompass Health is expected to report quarterly earnings of $1.20 per share, reflecting an 8.1% increase year-over-year, with revenues projected at $1.43 billion, a 9.7% rise from the previous year [3]. - The earnings report is scheduled for August 4, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Encompass Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.24%, suggesting a bearish sentiment among analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Encompass Health currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates predictions for beating the consensus EPS estimate [12]. Historical Performance - Encompass Health has consistently beaten consensus EPS estimates, achieving this in the last four quarters [14]. - In the last reported quarter, the company exceeded expectations by delivering earnings of $1.37 per share against an expected $1.19, resulting in a surprise of +15.13% [13]. Conclusion - While Encompass Health does not appear to be a compelling earnings-beat candidate, investors should consider various factors beyond earnings results when making investment decisions [17].

Core Viewpoint - Encompass Health Corporation is under investigation for potential securities fraud and unlawful business practices following allegations of poor performance in safety measures at its facilities, leading to a significant drop in stock price [1][2][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation regarding possible securities fraud or unlawful business practices [1]. - The New York Times reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [2]. Group 2: Stock Price Impact - Following the publication of the allegations, Encompass's stock price fell by $12.39 per share, representing a 10.35% decrease, closing at $107.28 per share on July 15, 2025 [3].

Core Viewpoint - Encompass Health Corp. has announced an increase in its quarterly dividend by $0.02, bringing the total to $0.19 per share, payable on October 15, 2025, to shareholders of record on October 1, 2025 [1]. Company Overview - Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, with a network of 169 hospitals across 38 states and Puerto Rico [2]. - The company is recognized for providing high-quality rehabilitative care, utilizing advanced technology and innovative treatments to aid patient recovery from major injuries or illnesses [2]. - Encompass Health has received accolades, being ranked among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America [2].

NEWTOWN, Pa., July 23, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Encompass Health Corporation ("Encompass") (NYSE: EHC), resulting from allegations of providing potentially misleading information to the investing public.If you are an Encompass investor who suffered a substantial loss and would like to learn more, you can provide your contact information and trading details HERE.You can also contact attorney Eric Lechtzin of Edels ...

Encompass Health (EHC) has been beaten down lately with too much selling pressure. While the stock has lost 10.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of ...

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. [Click here for information about joining the class action] On July 15, 2025, citing federal data and inspection reports, The New York Times published an article alleging that for-profit hospitals run by Encompass perform bel ...

Core Viewpoint - Encompass Health Corp. plans to build a new 40-bed inpatient rehabilitation hospital in Cleveland, Tennessee, expanding its network of rehabilitation facilities to better serve patients in the region [1][4]. Group 1: Hospital Details - The new hospital will focus on patients recovering from serious conditions such as strokes, neurological disorders, brain injuries, spinal cord injuries, amputations, and complex orthopedic issues [2]. - It will provide comprehensive care, including 24-hour nursing, physical, occupational, and speech therapies, delivered by specialized healthcare professionals [2]. - Facilities will include private patient rooms, a therapy gym with advanced rehabilitation technologies, an activities of daily living suite, an in-house dialysis suite, a dining room, a pharmacy, and a therapy courtyard [3]. Group 2: Strategic Importance - The hospital is expected to open in 2026 and will be a satellite location of the Encompass Health Rehabilitation Hospital of Chattanooga, enhancing local access to high-quality rehabilitative care [4]. - The expansion aligns with Encompass Health's strategy to provide compassionate care close to home for patients in Cleveland and surrounding communities [4]. Group 3: Company Overview - Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 169 hospitals across 38 states and Puerto Rico [5]. - The company is recognized for its high-quality rehabilitative care and innovative treatments, earning accolades such as being listed among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation due to allegations of violations of federal securities laws and poor performance on safety measures in their hospitals [1][3]. Group 1: Allegations and Investigations - A New York Times article reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [3]. - The investigation by Bragar Eagel & Squire focuses on whether Encompass has engaged in unlawful business practices related to these allegations [1][3]. Group 2: Stock Market Impact - Following the publication of the allegations, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share on July 15, 2025, resulting in financial harm to investors [4]. Group 3: Legal Support for Investors - Investors who purchased Encompass shares and suffered losses are encouraged to contact Bragar Eagel & Squire for potential legal recourse [5].

Core Viewpoint - Encompass Health Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following reports of safety concerns at its rehabilitation hospitals [1][3]. Group 1: Investigation Details - Kirby McInerney LLP is investigating claims against Encompass Health and its officers regarding possible violations of federal securities laws [1]. - The investigation was prompted by a New York Times article that highlighted significant safety issues at Encompass Health's hospitals, including high rates of preventable readmissions and serious operational mistakes [3]. Group 2: Financial Impact - Following the news of the investigation and safety concerns, Encompass Health's stock price fell by $12.39, approximately 10.4%, closing at $107.28 per share on July 15, 2025 [4].